Results 91 to 100 of about 709,465 (344)

Validation study of “Santé-Cerveau”, a digital tool for early cognitive changes identification

Alzheimer’s Research & Therapy, 2023
Background There is a need for a reliable, easy-to-use, widely available, and validated tool for timely cognitive impairment identification. We created a computerized cognitive screening tool (Santé-Cerveau digital tool (SCD-T)) including validated ...
Constance Lesoil, Stéphanie Bombois, Octave Guinebretiere, Marion Houot, Mahsa Bahrami, Marcel Levy, Rémy Genthon, Frédérique Bozon, Heidy Jean-Marie, Stéphane Epelbaum, Pierre Foulon, Nicolas Villain, Bruno Dubois   +12 more
doaj   +1 more source

Impact of APOE ε4 Genotype Load on Cognitive Function and Lipid Metabolism in Patients With Cerebral Small Vessel Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin, Haocheng Yang, Feng Liu, Sihao Lin, Junru Hu, Jian Wang, Yulan Gou   +6 more
wiley   +1 more source

Modeling Big Medical Survival Data Using Decision Tree Analysis with Apache Spark [PDF]

, 2019
In many medical studies, an outcome of interest is not only whether an event occurred, but when an event occurred; and an example of this is Alzheimer’s disease (AD).
Abdelqader, Ikhlas, Alsaedi, Abdalrahman, Altaie, Khulud, Delano, Mohammed Niaz, Fong, Alvis   +4 more
core   +1 more source

The effects of donepezil in Alzheimer's disease - Results from a multinational trial [PDF]

, 1999
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD).
Burns, A., Friedhoff, L. T., Gauthier, S., Hecker, J., Möller, Hans-Jürgen, Petit, H., Rogers, S. L., Rossor, M.   +7 more
core   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source

Variation in TMEM106B in chronic traumatic encephalopathy

Acta Neuropathologica Communications, 2018
The genetic basis of chronic traumatic encephalopathy (CTE) is poorly understood. Variation in transmembrane protein 106B (TMEM106B) has been associated with enhanced neuroinflammation during aging and with TDP-43-related neurodegenerative disease, and ...
Jonathan D. Cherry, Jesse Mez, John F. Crary, Yorghos Tripodis, Victor E. Alvarez, Ian Mahar, Bertrand R. Huber, Michael L. Alosco, Raymond Nicks, Bobak Abdolmohammadi, Patrick T. Kiernan, Laney Evers, Sarah Svirsky, Katharine Babcock, Hannah M. Gardner, Gaoyuan Meng, Christopher J. Nowinski, Brett M. Martin, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz, Robert A. Stern, Lindsay A. Farrer, Ann C. McKee, Thor D. Stein   +26 more
doaj   +1 more source

Quality of life evidence for patients with Alzheimer’s disease: use of existing quality of life evidence from the ADENA trials to estimate the utility impact of Exelon® [PDF]

This paper utilises the Mini-Mental State Examination (MMSE) score of patients with Alzheimer’s disease to establish a relationship between disease progression and quality of life measures, and the author also compares his results to findings from the ...
Brazier, J
core   +1 more source

Additional file 1: of Attitudes toward clinical trials across the Alzheimerâ s disease spectrum

, 2017
Appendix. (DOC 59 kb)
NuĂąo, Michelle, Gillen, Daniel, Dosanjh, Kulwant, Brook, Jenny, Elashoff, David, Ringman, John, Grill, Joshua   +6 more
openaire   +1 more source

The Relationship Between Inflammation and Central Nervous System in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Aim Multiple sclerosis is an autoimmune demyelination disease that is seen especially in the young population and has a progressive course, causing motor, sensory, and cognitive deficits. In the literature, the pathogenesis of MS disease and the interconnection between the immune and central nervous system in the disease have not been fully ...
Gamze Ansen, Ali Behram Salar, Abdulkadir Ermis, Erkingul Birday, Lutfu Hanoglu, Bayram Ufuk Sakul   +5 more
wiley   +1 more source

Quick assessment for systematic test statistic inflation/deflation due to null model misspecifications in genome-wide environment interaction studies.

PLoS ONE, 2019
Gene-environment (GxE) interaction is one potential explanation for the missing heritability problem. A popular approach to genome-wide environment interaction studies (GWEIS) is based on regression models involving interactions between genetic variants ...
Masao Ueki, Masahiro Fujii, Gen Tamiya, for Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer’s Disease Metabolomics Consortium   +3 more
doaj   +1 more source